Xiapex: new option for Dupuytren's contracture

The first injectable treatment for Dupuytren's contracture is now available.

Xiapex offers treatment for Dupuytren's contracture that works as an alternative to surgery
Xiapex offers treatment for Dupuytren's contracture that works as an alternative to surgery


Xiapex is a mixture of two collagenases produced by the bacterium C. histolyticum. The two enzymes have complementary substrate specificity, as they cleave interstitial collagen at different sites. The product is injected directly into the cord of tissue responsible for the contracture, causing collagen lysis and cord disruption.1


Two pivotal double-blind studies, CORD I and CORD II, evaluated the efficacy of collagenase C. histolyticum in adults with Dupuytren’s contracture with a palpable cord.

At study entry, patients had a finger flexion contracture of 20° or more and a positive 'table top test', defined as the inability to place the affected finger and palm flat against a table top. Patients were randomised to receive up to 3 injections of collagenase or placebo into the cord at 4-week intervals. If required, a finger extension procedure was performed to facilitate cord disruption.

Approximately four weeks after the last injection, the percentage of patients who had achieved the primary endpoint, a reduction in contracture to 5° or less, was significantly greater in the collagenase arm than in the placebo arm in both CORD I (64% vs 6.8%; p<0.001) and CORD II (44.4% vs 4.8%; p<0.001).1,2,3


  1. Xiapex Summary of Product Characteristics, February 2011.
  2. Hurst LC et al. N Engl J Med 2009; 361: 968–79.
  3. Gilpin D et al. J Hand Surg Am 2010; 35: 2027–38.

View Xiapex drug record

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...